Evaluating the Long-Term Cost-Effectiveness of the English NHS Diabetes Prevention Programme using a Markov Model

被引:0
|
作者
McManus, Emma [1 ]
机构
[1] Univ Manchester, Fac Biol Med & Hlth, Sch Hlth Sci, Hlth Org Policy & Econ,Div Populat Hlth Hlth Serv, Suite 12,Floor 7,Williamson Bldg,Oxford Rd, Manchester M13 9PL, England
关键词
LIFE-STYLE INTERVENTION; UNITED-KINGDOM; RISK; CARE; METFORMIN; ADULTS; IDENTIFICATION; STRATEGIES; MELLITUS; PEOPLE;
D O I
10.1007/s41669-024-00487-6
中图分类号
F [经济];
学科分类号
02 ;
摘要
Background In 2016, England launched the largest nationwide diabetes mellitus prevention programme, the NHS Diabetes Prevention Programme (NHS DPP). This paper seeks to evaluate the long-term cost-effectiveness of this programme.Methods A Markov cohort state transition model was developed with a 35-year time horizon and yearly cycles to compare referral to the NHS DPP to usual care for individuals with non-diabetic hyperglycaemia. The modelled cohort of individuals mirrored the age profile of referrals received by the programme by April 2020. A health system perspective was taken, with costs in UK pound Sterling (price year 2020) and outcomes in terms of quality-adjusted life-years (QALYs). Probabilistic analysis with 10,000 Monte Carlo simulations was used. Several sensitivity analyses were conducted to explore the uncertainty surrounding the base case results, particularly varying the length of time for which the effectiveness of the programme was expected to last.Results In the base case, using only the observed effectiveness of the NHS DPP at 3 years, it was found that the programme is likely to dominate usual care, by generating on average 40.8 incremental QALYs whilst saving 135,755 pound in costs for a cohort of 1000. At a willingness to pay of 20,000 pound per QALY, 98.1% of simulations were on or under the willingness-to-pay threshold. Scaling this up to the number of referrals actually received by the NHS DPP prior to April 2020, cost savings of 71.4 pound million were estimated over the 35-year time horizon and an additional 21,472 QALYs generated. These results are robust to several sensitivity analyses.Conclusion The NHS DPP is likely to be cost-effective. Indeed, in the majority of the simulations, the NHS DPP was cost-saving and generated greater QALYs, dominating usual care. This research should serve as evidence to support the continued investment or recommissioning of diabetes prevention programmes.
引用
收藏
页码:569 / 583
页数:15
相关论文
共 50 条
  • [41] Cost-effectiveness analysis of influenza and pneumococcal vaccination for Hong Kong elderly in long-term care facilities
    You, J. H. S.
    Wong, W. C. W.
    Ip, M.
    Lee, N. L. S.
    Ho, S. C.
    JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH, 2009, 63 (11) : 906 - 911
  • [42] Liraglutide Versus Lixisenatide: Long-Term Cost-Effectiveness of GLP-1 Receptor Agonist Therapy for the Treatment of Type 2 Diabetes in Spain
    Mezquita-Raya, Pedro
    Ramirez de Arellano, Antonio
    Kragh, Nana
    Vega-Hernandez, Gabriela
    Pohlmann, Johannes
    Valentine, William J.
    Hunt, Barnaby
    DIABETES THERAPY, 2017, 8 (02) : 401 - 415
  • [43] Long-Term Cost-Effectiveness of Smoking Cessation Interventions in People With Mental Disorders: A Dynamic Decision Analytical Model
    Wu, Qi
    Gilbody, Simon
    Li, Jinshuo
    Wang, Han-, I
    Parrott, Steve
    VALUE IN HEALTH, 2021, 24 (09) : 1263 - 1272
  • [44] Cost-Effectiveness of Angiotensin-Converting Enzyme Inhibitors for the Prevention of Diabetic Nephropathy in The Netherlands - A Markov Model
    Adarkwah, Charles Christian
    Gandjour, Afschin
    Akkerman, Maren
    Evers, Silvia M.
    PLOS ONE, 2011, 6 (10):
  • [45] Evaluation of the long-term cost-effectiveness of liraglutide vs lixisenatide for treatment of type 2 diabetes mellitus in the UK setting
    Hunt, Barnaby
    Vega-Hernandez, Gabriela
    Valentine, William J.
    Kragh, Nana
    DIABETES OBESITY & METABOLISM, 2017, 19 (06) : 842 - 849
  • [46] Long-Term Cost-Effectiveness of Case Finding and Mass Screening for Celiac Disease in Children
    Suasnabar, Jan Heijdra
    Meijer, Caroline R.
    Smit, Lucy
    van Overveld, Floris
    Thom, Howard
    Keeney, Edna
    Mearin, M. Luisa
    van den Akker-van Marle, M. Elske
    GASTROENTEROLOGY, 2024, 167 (06) : 1129 - 1140
  • [47] Long-term use and cost-effectiveness of secondary prevention drugs for heart disease in Western Australian seniors (WAMACH): a study protocol
    Gunnell, Anthony S.
    Knuiman, Matthew W.
    Geelhoed, Elizabeth
    Hobbs, Michael S. T.
    Katzenellenbogen, Judith M.
    Hung, Joseph
    Rankin, Jamie M.
    Nedkoff, Lee
    Briffa, Thomas G.
    Ortiz, Michael
    Gillies, Malcolm
    Cordingley, Anne
    Messer, Mitch
    Gardner, Christian
    Lopez, Derrick
    Atkins, Emily
    Mai, Qun
    Sanfilippo, Frank M.
    BMJ OPEN, 2014, 4 (09):
  • [48] Evaluation of the long-term cost-effectiveness of insulin detemir compared with neutral protamine hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in Sweden
    Valentine, William J.
    Aagren, Mark
    Haglund, Mattias
    Ericsson, Asa
    Gschwend, Manuela H.
    SCANDINAVIAN JOURNAL OF PUBLIC HEALTH, 2011, 39 (01) : 79 - 87
  • [49] Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme
    Stephen C. Bain
    Brian B. Hansen
    Samuel J. P. Malkin
    Solomon Nuhoho
    William J. Valentine
    Barrie Chubb
    Barnaby Hunt
    Matthew Capehorn
    Diabetes Therapy, 2020, 11 : 259 - 277
  • [50] Long-Term Cost-Effectiveness Analyses of Empagliflozin Versus Oral Semaglutide, in Addition to Metformin, for the Treatment of Type 2 Diabetes in the UK
    Mafalda Ramos
    Michael H. Cummings
    Anastasia Ustyugova
    Syed I. Raza
    Shamika U. de Silva
    Mark Lamotte
    Diabetes Therapy, 2020, 11 : 2041 - 2055